On February 17, 2026, the Health Resources and Services Administration (HRSA) issued a request for information (RFI) seeking comment on the use of manufacturer rebates to establish ceiling prices for drugs in the federal 340B program.
The RFI was seen by regulatory observers as an early indication that the Trump administration intended